By discovering and developing novel medicines to treat aggressive diseases, including advanced, treatment resistant cancers, we aim to improve and save lives and thereby create value for patients, society, and shareholders. Sustainability is therefore the foundation of our activities and directly linked to our long-term success. We are committed to the UN Sustainable Development Goals (SDGs) and our vision is directed to contributing to SDG 3 – health and wellbeing. Through our work we are also contributing to SDG 8 – decent work and economic growth, SDG 9 – industry, innovation and infrastructure, and SDG 17 – partnerships for the goals.
In order to have a real and meaningful impact, we worked in 2020 to strengthen our sustainability management. The aim was to identify ESG (Environmental, Social and Governance) activities in BerGenBio’s value chain that are material for us and our stakeholders. Our key stakeholders include patients and their families, our employees, investors, regulators, suppliers and other business partners, such as research organisations and academic institutions.
The work involved mapping of our value chain, review of industry standards, organisations and peers. In addition, we engaged with key stakeholders and consulted ESG experts in order to gain insight into what is important to our stakeholders and their expectations of us. The matrix below, provides an overview of the resulting material ESG topics that are deemed important for our long-term sustained value creation.
The topics in the right hand corner are those which are of most strategic importance to BerGenBio. These are given detailed descriptions in the Annual Report 2020.
- Innovation and clinical trial conduct are addressed in the “Performance” section in the Strategic Report of the Annual Report 2020.
- Business ethics is addressed in the Corporate Governance section of the Annual Report and in the Board of Directors’ report.
- Economic performance is addressed in the Financial Statements.
- Patient health and safety along with the remaining topics are covered in the ESG section in the Board of Directors’ report.
A reference index of the reporting is provided in the appendix for ease of location.
BerGenBio is committed to build our business in line with international best practice on ESG. Going forward, we will further integrate the material ESG topics into our strategy and governance including setting strategic ESG targets and incorporating additional metrics. We have now established a foundation which will grow with us to ensure our sustainable value creation as our company further develops.